Top Suppliers:I want be here



163521-12-8

163521-12-8 structure
163521-12-8 structure
  • Name: Vilazodone
  • Chemical Name: vilazodone
  • CAS Number: 163521-12-8
  • Molecular Formula: C26H27N5O2
  • Molecular Weight: 441.52
  • Catalog: Signaling Pathways GPCR/G Protein 5-HT Receptor
  • Create Date: 2018-06-08 17:44:52
  • Modify Date: 2024-01-02 13:44:05
  • Vilazodone (EMD 68843; SB 659746A) is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation for the treatment of major depression.IC50 value:Target: SSRI; 5-HT1AVilazodone represents another option for the treatment of MDD. Vilazodone appears to have a favourable weight-gain profile based on short-term studies. Sexual side-effects were not consistently demonstrated when assessed using clinical rating scales but spontaneously reported AEs related to sexual functioning were observed. Additional controlled data regarding long-term efficacy and effectiveness will help characterise this new agent when used in maintenance treatment.

Name vilazodone
Synonyms 5-{4-[4-(5-Cyano-1H-indol-3-yl)butyl]-1-piperazinyl}-1-benzofuran-2-carboxamide
2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-
Viibryd
5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide
5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide
5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide
vilazodone
Description Vilazodone (EMD 68843; SB 659746A) is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation for the treatment of major depression.IC50 value:Target: SSRI; 5-HT1AVilazodone represents another option for the treatment of MDD. Vilazodone appears to have a favourable weight-gain profile based on short-term studies. Sexual side-effects were not consistently demonstrated when assessed using clinical rating scales but spontaneously reported AEs related to sexual functioning were observed. Additional controlled data regarding long-term efficacy and effectiveness will help characterise this new agent when used in maintenance treatment.
Related Catalog
References

[1]. Cruz MP. Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.

[2]. Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J C

[3]. Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Curr Med Res Opin. 2012 Jan;28(1):27-39.

[4]. Lee A. Dawson et al. Vilazodone: A 5-HT1A Receptor Agonist/Serotonin Transporter Inhibitor for the Treatment of Affective Disorders CNS Neuroscience & Therapeutics Volume 15, Issue 2, pages 107-117, June 2009

[5]. Thomas L. Schwartz Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor Therapeutic Advances in Psychopharmacology June 2011 vol. 1 no. 3 81-87

Density 1.34 g/cm3
Boiling Point 745.1ºC at 760 mmHg
Melting Point 203-205ºC
Molecular Formula C26H27N5O2
Molecular Weight 441.52
PSA 102.29000
LogP 5.53478
Storage condition -20°C